EUVIMEDEUVIMED entdecken
Leserbrief

Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer

Hirotaka Suto iD

Journal of Clinical Oncology · 20.11.2026 · 44 (33) · 3284-3284

DOI: 10.1200/jco-26-01219 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.11.2026. Verfasst von Hirotaka Suto. Beteiligte Einrichtung: Hirotaka Suto, MD, PhD, Department of Medical Oncology, Hyogo Cancer Center, Akashi, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 4 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Hirotaka Suto, MD, PhD, Department of Medical Oncology, Hyogo Cancer Center, Akashi, Japan.

ORCID-Profile: Hirotaka Suto

Zitieren

APA

Suto, H. (2026). Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer. Journal of Clinical Oncology, 44(33), 3284-3284. https://doi.org/10.1200/jco-26-01219

Vancouver

Suto H. Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer. Journal of Clinical Oncology. 2026;44(33):3284-3284. doi:10.1200/jco-26-01219

BibTeX
@article{Suto2026,
  author = {Suto, Hirotaka},
  title = {Therapeutic Strategy Concerns for BRAF V600E–Mutated Differentiated Thyroid Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {33},
  pages = {3284--3284},
  doi = {10.1200/jco-26-01219}
}
Kostenlos starten →